Research Examines Efficacy Of Sglt2 Inhibitor As 2ndline Diabetes Therapy | Latest News RSS feed

Research Examines Efficacy Of Sglt2 Inhibitor As 2ndline Diabetes Therapy - Latest News

Merck's Diabetes Pipeline Candidates Are Sure Bets; Only A Matter Of When

Diabetes is a global health problem, and more than 29 million people in the U.S. have diabetes. This article examines the Merck (NYSE ... Ertugliflozin is a sodium-glucose co-transporter 2 (SGLT2) inh... read more

AstraZeneca to Highlight Scientific Advancements Across Its Diabetes Portfolio at the American Diabetes Association 76 th Scientific Sessions

The studies to be presented evaluate the management of multiple risk factors associated with type 2 diabetes ... SGLT-2 inhibitors, GLP-1 receptor agonists and DPP-4 inhibitors. As a strategic therapy ... read more

Metformin and other antidiabetic agents in renal failure patients

Glinides have modest glycemic efficacy and lack clinical outcome data. Insulin is the most effective therapy for patients with diabetes. The need for subcutaneous ... impaired kidney function. 130 III ... read more

Looking for another news?

Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes

1 Translational Research Institute ... as well as safety and efficacy data, and considering patient convenience and personal choices, it appears that SGLT2 inhibitors would be a reasonable alternative ... read more

Buy vTv Therapeutics For Its Novel Alzheimer's And Anti-Diabetic Drug Candidates.

Extensive research has now shown that dysfunction of the GK enzyme may lead to development of type II diabetes. In preclinical studies, drugs targeting the activation of GK enzyme have shown efficacy ... read more

Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes

1 Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 2 Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public ... read more

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin

Address all correspondence and requests for reprints to: John P. Bilezikian, MD, College of Physicians & Surgeons, Department of Medicine, 622 West 168th Street, New York, NY 10032. E-mail: jpb2@cumc. ... read more

A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats

In contrast, SGLT2 ... inhibitor tofogliflozin significantly increased food intake in rats. 32 Previous studies have shown that SGLT2 expression in urinary exfoliated proximal tubular cells was signif... read more

Dr. Steven Kahn

Dr. Steven Kahn is an endocrinologist in Seattle, Washington and is affiliated with University of Washington Medical Center. He is one of 37 doctors at University of Washington Medical Center who spec... read more

Standards of Medical Care in Diabetes—2015 Abridged for Primary Care Providers

The tables, figures, and references have been renumbered from the original document. The complete 2015 Standards supplement is available at read more

Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline

Many medications commonly prescribed for diabetes, depression, and other chronic diseases have weight effects, either to promote weight gain or produce weight loss. Knowledgeable prescribing of medica... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us